These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 18689611)

  • 1. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS).
    Liang Y; Shaw AM; Boules M; Briody S; Robinson J; Oliveros A; Blazar E; Williams K; Zhang Y; Carlier PR; Richelson E
    J Pharmacol Exp Ther; 2008 Nov; 327(2):573-83. PubMed ID: 18689611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
    Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
    J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.
    Golembiowska K; Kowalska M; Bymaster FP
    Synapse; 2012 May; 66(5):435-44. PubMed ID: 22213370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.
    Shaw AM; Boules M; Zhang Y; Williams K; Robinson J; Carlier PR; Richelson E
    Eur J Pharmacol; 2007 Jan; 555(1):30-6. PubMed ID: 17109850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
    Dutta AK; Ghosh B; Biswas S; Reith ME
    Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
    Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
    PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor.
    Hou J; Xing Y; Zuo D; Wu Y; Tian J; Meng Q; Yang M
    Physiol Behav; 2015 Jan; 138():141-9. PubMed ID: 25447484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
    Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
    Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
    Brennan JA; Graf R; Grauer SM; Navarra RL; Pulicicchio CM; Hughes ZA; Lin Q; Wantuch C; Rosenzweig-Lipson S; Pruthi F; Lai M; Smith D; Goutier W; van de Neut M; Robichaud AJ; Rotella D; Feenstra RW; Kruse C; Broqua P; Beyer CE; McCreary AC; Pausch MH; Marquis KL
    J Pharmacol Exp Ther; 2010 Jan; 332(1):190-201. PubMed ID: 19828876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test.
    O'Leary OF; Bechtholt AJ; Crowley JJ; Hill TE; Page ME; Lucki I
    Psychopharmacology (Berl); 2007 Jun; 192(3):357-71. PubMed ID: 17318507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties.
    Artaiz I; Zazpe A; Innerárity A; Del Olmo E; Díaz A; Ruiz-Ortega JA; Castro E; Pena R; Labeaga L; Pazos A; Orjales A
    Psychopharmacology (Berl); 2005 Nov; 182(3):400-13. PubMed ID: 16032410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor.
    Xue R; Jin ZL; Chen HX; Yuan L; He XH; Zhang YP; Meng YG; Xu JP; Zheng JQ; Zhong BH; Li YF; Zhang YZ
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):728-41. PubMed ID: 22748419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor.
    Jin ZL; Gao N; Li XR; Tang Y; Xiong J; Chen HX; Xue R; Li YF
    Eur Neuropsychopharmacol; 2015 Apr; 25(4):544-56. PubMed ID: 25638027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors.
    Dekeyne A; Gobert A; Auclair A; Girardon S; Millan MJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):156-67. PubMed ID: 12110993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats.
    Zhang R; Li X; Shi Y; Shao Y; Sun K; Wang A; Sun F; Liu W; Wang D; Jin J; Li Y
    PLoS One; 2014; 9(3):e91775. PubMed ID: 24614602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple reuptake inhibition of serotonin, norepinephrine, and dopamine increases the tonic activation of α
    Jiang JL; El Mansari M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Dec; 103():109987. PubMed ID: 32474007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
    Wong EH; Sonders MS; Amara SG; Tinholt PM; Piercey MF; Hoffmann WP; Hyslop DK; Franklin S; Porsolt RD; Bonsignori A; Carfagna N; McArthur RA
    Biol Psychiatry; 2000 May; 47(9):818-29. PubMed ID: 10812041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action.
    Smolders I; Clinckers R; Meurs A; De Bundel D; Portelli J; Ebinger G; Michotte Y
    Neuropharmacology; 2008 May; 54(6):1017-28. PubMed ID: 18378264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening.
    Talbot JN; Geffert LM; Jorvig JE; Goldstein RI; Nielsen CL; Wolters NE; Amos ME; Munro CA; Dallman E; Mereu M; Tanda G; Katz JL; Indarte M; Madura JD; Choi H; Leak RK; Surratt CK
    Pharmacol Biochem Behav; 2016; 150-151():22-30. PubMed ID: 27569602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropharmacological and antidepressant-like effects of ZY-1408: A novel serotonin/norepinephrine reuptake inhibitor and serotonin receptor 2C antagonist.
    Gao N; Tiliwaerde M; Zheng W; Xiong J; Li X; Jin Z
    Neuropharmacology; 2021 Jan; 182():108376. PubMed ID: 33122031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.